Myeloablative Autologous Stem-Cell Transplantation for Severe SclerodermaKeith Sullivan, Daniel E. Furst, Ellen Goldmuntz et al.|New England Journal of Medicine|2018Cited by 584
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Ye Li et al.|Nature Medicine|2024Cited by 452
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II TrialPhilippe Armand, Leo I. Gordon, Arnon Nagler et al.|Journal of Clinical Oncology|2013Cited by 439
Optimizing Autologous Stem Cell Mobilization Strategies to Improve Patient Outcomes: Consensus Guidelines and RecommendationsSergio Giralt, Steven M. Devine, Finn Bo Petersen et al.|Biology of Blood and Marrow Transplantation|2013Cited by 402
CRP and ferritin in addition to the EASIX score predict CAR-T–related toxicityUri Greenbaum, Sairah Ahmed, Paolo Strati et al.|Blood Advances|2021Cited by 146